Desirudin dosing and monitoring in moderate renal impairment

Journal of Clinical Pharmacology

Volumn 50, Issue 6, 2010, Pages 614-622

  Nafziger, Anne N ^a   Bertino Jr , Joseph S ^a  

^a BERTINO CONSULTING   (United States)

Author keywords

Administration and dosage; Analogs and derivatives; Anticoagulants; Drug therapy; Hirudins; Kidney failure; Thrombophlebitis

Indexed keywords

DESULFATOHIRUDIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MAXIMUM ALLOWABLE CONCENTRATION; SINGLE DRUG DOSE;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HIRUDINS; HUMANS; INJECTIONS, SUBCUTANEOUS; MONTE CARLO METHOD; PARTIAL THROMBOPLASTIN TIME; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY;

EID: 77953769708     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009350626     Document Type: Article

References (37)

1. Iprivask (desirudin) 15 mg subcutaneous injection. Collegeville, PA: Canyon Pharmaceuticals ; 2000.
2. Iprivask [package insert]. 2000. http://www.fda.gov/cder/foi/label/2003/ 21271-iprivask-lbl.pdf. Accessed March 7, 2009.
3. Lefevre G., Duval M., Gauron S., et al. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clin Pharmacol Ther. 1997 ; 62: 50-59.
4. Lefevre G., Piraino AJ, Brookman LJ A Comparative Evaluation of the Pharmacokinetics and Pharmacodynamics of CGP 39 393, Given Intravenously Over a Period of 30 Minutes to Subjects With Normal Renal Functions and to Subjects With Varying Degrees of Renal Insufficiency. Rueil-Malmaison, France: Ciba-Geigy Pharmaceuticals ; 1995. US08B.
5. Walker SM A Pharmacokinetic and Pharmacodynamic Study After a Single Subcutaneous Administration of CGP 39 393 (Recombinant Hirudin) to Twelve Healthy Elderly Volunteers. Horsham, UK: Ciba-Geigy Pharmaceuticals ; 1992. UK R2/1992.
6. Walker SM Single Dose Comparison of One Subcutaneous and One Intravenous Administration of Recombinant Hirudin (CGP 39 393), at Two Dose Levels, in Healthy Volunteers Never Previously Exposed to Hirudin. Rueil-Malmaison, France: Ciba-Geigy Pharmaceuticals ; 1990. RH/E10.
7. Lefevre G., Czendlik CH, Racine A. Single Dose, Open-Label, Two-Period, Randomized, Crossover Bioequivalence Study of the Two Subcutaneous CGP 39 393 Formulations F1 and F4 in Twelve Healthy Male Volunteers. Rueil-Malmaison, France: Ciba-Geigy Pharmaceuticals ; 1995. RH/E36.
8. Close P., Graf P., Bach D. An Open, Comparative, Single-Dose Trial (Two Intravenous Applications) With CGP 39 393 in Healthy Volunteers Never Previously Exposed To Hirudin. Basel, Switzerland: Ciba-Geigy Limited ; 1990.
9. Ekman S., Close P., Bach D., Eriksson BI A Multicenter Double-Blind Randomized Heparin Controlled Dose-Finding Trial Evaluating the Efficacy of Three CGP 39 393 Dose Levels in Patients Undergoing an Elective Total Hip Replacement. Basel, Switzerland: Ciba-Geigy Limited ; 1994. RH/E23.
10. Eriksson BI, Ekman S., Lindbratt S., et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg. 1997 ; 79: 326-333.
11. Wagner JG Fundamentals of Clinical Pharmacokinetics. Hamilton, IL: Drug Intelligence Publications; 1975.
12. Weitz JI, Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990 ; 86: 385-391.
13. Weitz JI, Leslie B., Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 1998 ; 97: 544-552.
14. Eriksson BI, Ekman S., Kalebo P., Zachrisson B., Bach D., Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996 ; 347: 635-639.
15. Matheson AJ, Goa KL Desirudin: a review of its use in the management of thrombotic disorders. Drugs. 2000 ; 60: 679-700.
16. Eriksson BI, Wille-Jorgensen P., Kalebo P., et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997 ; 337: 1329-1335.
17. Desirudin (Iprivask). [product information]. http://www.fda.gov/cder/foi/ label/2003/021271lbl.pdf Accessed October 27, 2009.
18. Levin LA, Horst M., Bergqvist D. Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery. PharmacoEconomics. 1998 ; 13 (pt 2). 111-118.
19. Levin LA, Bergqvist D. Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery. PharmacoEconomics. 2001 ; 19 (pt 2). 589-597.
20. Hirsh J., Bauer KA, Donati MB, Gould M., Samama MM, Weitz JI Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th edition). Chest. 2008 ; 133 (suppl). 141S - 159S. (Pubitemid 351892966)
21. Warkentin TE Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res. 2003 ; 110 (2-3). 73-82.
22. Bichler J., Baynes JW, Thorpe SR Catabolism of hirudin and thrombin-hirudin complexes in the rat. Biochem J. 1993 ; 296 (pt 3). 771-776.
23. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother. 1992 ; 26: 1535-1540.
24. Fischer KG The role of recombinant hirudins in the management of thrombotic disorders. BioDrugs. 2004 ; 18: 235-268.
25. Bocci V. Catabolism of therapeutic proteins and peptides with implications for drug delivery. Adv Drug Deliv Rev. 1990 ; 4: 149-169.
26. Fischer KG Hirudin in renal insufficiency. Semin Thromb Hemost. 2002 ; 28: 467-482.
27. Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. 2 nd ed. New York: Marcel Dekker ; 2001.
28. Talbot MD, Ambler J., Butler KD, et al. Recombinant desulphatohirudin (CGP 39393): comparative studies with standard and low molecular weight heparin. In: Zilla P, Fasol C, Callow A, eds. International Society for Applied Cardiovascular Biology. Vol 1. Basel, Switzerland: Karger ; 1989: 131-146.
29. Anand SS, Yusuf S., Pogue J., Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation. 2003 ; 107: 2884-2888.
30. Schulman S., Beyth RJ, Kearon C., Levine MN Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8 th edition). Chest. 2008 ; 133 (suppl). 257S - 298S.
31. Marbet GA, Verstraete M., Kienast J., et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol. 1993 ; 22: 364-372.
32. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation. 1994 ; 90: 1631-1637.
33. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med. 1996 ; 335: 775-782.
34. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998 ; 122: 782-798.
35. Harrisonĝ€™s Online. In: Fauci AS, Braunwald E, Kasper DL, et al., eds. Harrisonĝ€™s Principles of Internal Medicine. 17 th ed. New Yok: McGraw-Hill ; 2008.
36. Bonate PL A brief introduction to Monte Carlo simulation. Clin Pharmacokinet. 2001 ; 40: 15-22.
37. Bichler J., Fichtl B., Siebeck M., Fritz H. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzneimittel-Forschung. 1988 ; 38: 704-710.